Loading...

Edward B Garon

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
Address760 Westwood Plaza 32-144
Los Angeles CA 90024
Phone(310) 586-2098
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    A model for predicting response to PD-1 inhibitors in NSCLC
    NIH/NCI R01CA208403Jan 3, 2017 - Dec 31, 2021
    Role: Principal Investigator
    Inhibiting EGFR and ER pathways in NSCLC
    NIH/NCI K23CA149079Jul 15, 2011 - Jun 30, 2016
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Osimertinib Plus Ramucirumab: The Best of Both Worlds? Clin Cancer Res. 2020 Dec 17. Garon EB. PMID: 33334907.
      View in: PubMed   Mentions:    Fields:    
    2. Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. Lung Cancer. 2021 01; 151:25-29. Garon EB, Kim JS, Govindan R. PMID: 33285468.
      View in: PubMed   Mentions:    Fields:    
    3. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2020 Oct 20. Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, Heymach JV, Garon EB. PMID: 33096270.
      View in: PubMed   Mentions:    Fields:    
    4. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Front Oncol. 2020; 10:572895. Liu HE, Vuppalapaty M, Wilkerson C, Renier C, Chiu M, Lemaire C, Che J, Matsumoto M, Carroll J, Crouse S, Hanft VR, Jeffrey SS, Di Carlo D, Garon EB, Goldman J, Sollier E. PMID: 33117705.
      View in: PubMed   Mentions:
    5. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. Cancer Sci. 2020 Sep 20. Nishio M, Seto T, Reck M, Garon EB, Chiu CH, Yoh K, Imamura F, Park K, Shih JY, Visseren-Grul C, Frimodt-Moller B, Zimmermann A, Homma G, Enatsu S, Nakagawa K. PMID: 32954593.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020 Nov 20; 38(33):3863-3873. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G, Gunuganti V, Li A, Aanur N, Spigel DR. PMID: 32910710.
      View in: PubMed   Mentions:    Fields:    
    7. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 09 03; 383(10):944-957. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS. PMID: 32877583.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    8. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020 Oct; 36(10):1667-1675. Yoh K, Atagi S, Reck M, Garon EB, Ponce Aix S, Moro-Sibilot D, Winfree KB, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Nakagawa K. PMID: 32780643.
      View in: PubMed   Mentions:    Fields:    
    9. Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001. Ann Transl Med. 2020 Jun; 8(11):728. Akingbemi W, Garon E. PMID: 32617347.
      View in: PubMed   Mentions:
    10. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 May 01; 6(5):661-674. Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S. PMID: 32271377.
      View in: PubMed   Mentions: 10     Fields:    
    11. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. Support Care Cancer. 2021 Jan; 29(1):117-125. Garon EB, Winfree KB, Molife C, Cui ZL, Arriola E, Levy B, Mekhail T, Pérol M. PMID: 32318871.
      View in: PubMed   Mentions:    Fields:    
    12. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol. 2020 06; 15(6):914-947. Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. PMID: 32179179.
      View in: PubMed   Mentions: 17     Fields:    
    13. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 May 10; 38(14):1505-1517. Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC. PMID: 32150489.
      View in: PubMed   Mentions: 20     Fields:    
    14. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020 May 10; 38(14):1580-1590. Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P. PMID: 32078391.
      View in: PubMed   Mentions: 8     Fields:    
    15. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 03; 21(3):387-397. Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodríguez-Abreu D. PMID: 32035514.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    16. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO Open. 2020 01; 5(1). Garon EB, Scagliotti GV, Gautschi O, Reck M, Thomas M, Iglesias Docampo L, Kalofonos H, Kim JH, Gans S, Brustugun OT, Orlov SV, Cuyun Carter G, Zimmermann AH, Oton AB, Alexandris E, Lee P, Wolff K, Stefaniak VJ, Socinski MA, Pérol M. PMID: 31958290.
      View in: PubMed   Mentions:
    17. KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. Transl Lung Cancer Res. 2019 Dec; 8(Suppl 4):S403-S406. Cummings AL, Garon EB. PMID: 32038925.
      View in: PubMed   Mentions:
    18. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 12; 20(12):1655-1669. Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M. PMID: 31591063.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    19. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. PMID: 31563517.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    20. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2019 09 15; 200(6):e31-e43. Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. PMID: 31518182.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    21. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019 10 01; 37(28):2518-2527. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. PMID: 31154919.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    22. Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer. 2019 09; 135:104-109. Noor ZS, Goldman JW, Lawler WE, Telivala B, Braiteh F, DiCarlo BA, Kennedy K, Adams B, Wang X, Jones B, Slamon DJ, Garon EB. PMID: 31446981.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). J Thorac Oncol. 2019 09; 14(9):1628-1639. Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA. PMID: 31121324.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    25. Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. Transl Lung Cancer Res. 2019 Apr; 8(2):195-197. Lisberg A, Garon EB. PMID: 31106131.
      View in: PubMed   Mentions:
    26. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019 04; 7(4):347-357. Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. PMID: 30876831.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    27. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncol. 2019 May; 15(13):1481-1491. Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS. PMID: 30839234.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer. Lung Cancer. 2019 05; 131:6-13. Pérol M, Winfree KB, Cuyun Carter G, Lin Cui Z, Bowman L, Garon EB. PMID: 31027699.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    29. Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story. J Thorac Oncol. 2019 02; 14(2):160-162. Goldman JW, Garon EB. PMID: 30683290.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019 05; 14(5):793-801. Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS. PMID: 30711649.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    31. Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer? J Clin Oncol. 2019 03 01; 37(7):529-536. Lisberg A, Garon EB. PMID: 30676857.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation. JCO Clin Cancer Inform. 2018 12; 2:1-12. Fares CM, Williamson TJ, Theisen MK, Cummings A, Bornazyan K, Carroll J, Spiegel ML, Stanton AL, Garon EB. PMID: 30652613.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    33. Torsades de pointes with pseudo-T wave alternans during rociletinib therapy: A novel manifestation of a rare side effect. HeartRhythm Case Rep. 2018 Oct; 4(10):490-493. Teng AE, Share M, Hsu JJ, Rettinger SR, Garon E, Goldman J, Yang EH, Tung R. PMID: 30364475.
      View in: PubMed   Mentions:
    34. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018 07 17; 6(1):75. Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. PMID: 30012210.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    35. A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. J Thorac Oncol. 2018 09; 13(9):1284-1293. Williamson TJ, Choi AK, Kim JC, Garon EB, Shapiro JR, Irwin MR, Goldman JW, Bornyazan K, Carroll JM, Stanton AL. PMID: 29981926.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. J Thorac Oncol. 2018 08; 13(8):1058-1059. Lisberg A, Garon EB. PMID: 30056858.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    37. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. PMID: 30089602.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    38. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res. 2018 12 01; 24(23):5841-5849. Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA. PMID: 29891725.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    39. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1138-1145. Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. PMID: 29874546.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    40. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2018 07; 82(1):77-86. Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M. PMID: 29721850.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    41. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31; 378(22):2078-2092. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC. PMID: 29658856.
      View in: PubMed   Mentions: 685     Fields:    Translation:HumansCTClinical Trials
    42. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, Tsao A, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon E. PMID: 29748017.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    43. A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):564-573. Sandler KA, Abtin F, Suh R, Cook RR, Felix C, Lee JM, Garon EB, Wu J, Luterstein EM, Agazaryan N, Tenn SE, Lee C, Steinberg ML, Lee P. PMID: 29893274.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    44. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol. 2018 05; 13(5):682-688. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. PMID: 29518553.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    45. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep. 2018 02 07; 8(1):2592. Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. PMID: 29416054.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    46. High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. J Thorac Dis. 2018 Feb; 10(Suppl 3):S397-S403. Ellis-Caleo T, Lisberg A, Tucker DA, Garon EB. PMID: 29593885.
      View in: PubMed   Mentions:
    47. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res. 2018 03; 6(3):288-294. Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. PMID: 29382669.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    48. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Clin Lung Cancer. 2018 05; 19(3):270-279.e3. Ramalingam SS, Pérol M, Reck M, Kowalyszyn RD, Gautschi O, Kimmich M, Cho EK, Czyzewicz G, Grigorescu A, Karaseva N, Dakhil S, Lee P, Zimmerman A, Sashegyi A, Alexandris E, Carter GC, Winfree KB, Garon EB. PMID: 29373274.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    49. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 04; 13(4):576-584. Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB. PMID: 29247830.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    50. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. Radiology. 2018 04; 287(1):326-332. Tsai EB, Pomykala K, Ruchalski K, Genshaft S, Abtin F, Gutierrez A, Kim HJ, Li A, Adame C, Jalalian A, Wolf B, Garon EB, Goldman JW, Suh R. PMID: 29232184.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    51. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018 02 02; 359(6375):582-587. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. PMID: 29217585.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCells
    52. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. PMID: 29217530.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    53. Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. Transl Lung Cancer Res. 2017 Dec; 6(Suppl 1):S39-S40. Lisberg A, Garon EB. PMID: 29299407.
      View in: PubMed   Mentions:
    54. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4. Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. PMID: 29317191.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    55. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15; 123(24):4800-4807. Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. PMID: 29125624.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. Evaluating Casama: Contextualized semantic maps for summarization of lung cancer studies. Comput Biol Med. 2018 01 01; 92:55-63. Garcia-Gathright JI, Matiasz NJ, Adame C, Sarma KV, Sauer L, Smedley NF, Spiegel ML, Strunck J, Garon EB, Taira RK, Aberle DR, Bui AAT. PMID: 29149658.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? Cancer Biol Med. 2017 Nov; 14(4):341-347. Cummings AL, Garon EB. PMID: 29372100.
      View in: PubMed   Mentions:
    58. Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. N Engl J Med. 2017 06 22; 376(25):2483-2485. Garon EB. PMID: 28636845.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    59. Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2018 01; 19(1):e19-e28. Gaut D, Sim MS, Yue Y, Wolf BR, Abarca PA, Carroll JM, Goldman JW, Garon EB. PMID: 28712979.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    60. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer. 2017 10; 112:126-133. Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Carter GC, Alexandris E, Garon EB. PMID: 29191585.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    61. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 07; 18(7):895-903. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. PMID: 28551359.
      View in: PubMed   Mentions: 177     Fields:    Translation:HumansCTClinical Trials
    62. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15; 23(16):4556-4568. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. PMID: 28468947.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    63. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. PMID: 28411193.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCellsCTClinical Trials
    64. Biophysical isolation and identification of circulating tumor cells. Lab Chip. 2017 04 11; 17(8):1452-1461. Che J, Yu V, Garon EB, Goldman JW, Di Carlo D. PMID: 28352869.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    65. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 2017 04; 106:76-82. Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, Nadanaciva S, O'Connell J, Sbar E, Cho BC. PMID: 28285698.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    66. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep. 2017 01 17; 18(3):601-610. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. PMID: 28099841.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    67. A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Onco Targets Ther. 2016; 9:7275-7283. Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F. PMID: 27942221.
      View in: PubMed   Mentions:
    68. Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells. Sci Rep. 2016 10 14; 6:35474. Dhar M, Pao E, Renier C, Go DE, Che J, Montoya R, Conrad R, Matsumoto M, Heirich K, Triboulet M, Rao J, Jeffrey SS, Garon EB, Goldman J, Rao NP, Kulkarni R, Sollier-Christen E, Di Carlo D. PMID: 27739521.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    69. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opin Biol Ther. 2016 12; 16(12):1479-1489. Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O'brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. PMID: 27650132.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    70. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):96-99. Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. PMID: 27894601.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    71. The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 May 01; 2(5):571-572. Lisberg A, Garon EB. PMID: 26986923.
      View in: PubMed   Mentions: 6     Fields:    
    72. Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. Oncotarget. 2016 Mar 15; 7(11):12748-60. Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, Garon EB, Goldman J, Rao J, Sledge GW, Pegram MD, Sheth S, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D. PMID: 26863573.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    73. The race for combined checkpoint inhibition in NSCLC. Lancet Oncol. 2016 Mar; 17(3):259-260. Garon EB. PMID: 26858123.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer. 2016 Mar; 93:95-103. Pérol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB. PMID: 26898621.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    75. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 01; 122(5):766-72. Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. PMID: 26695526.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    76. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 09; 387(10027):1540-1550. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. PMID: 26712084.
      View in: PubMed   Mentions: 1347     Fields:    Translation:Humans
    77. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Semin Oncol. 2015 Oct; 42 Suppl 2:S11-8. Garon EB. PMID: 26477470.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    78. Selecting patients for immune checkpoint inhibition in lung cancer. Clin Adv Hematol Oncol. 2015 Aug; 13(8):490-2. Garon EB. PMID: 26351808.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    79. Patient Portal Preferences: Perspectives on Imaging Information. J Assoc Inf Sci Technol. 2015 Aug 01; 66(8):1606-1615. McNamara M, Arnold C, Sarma K, Aberle D, Garon E, Bui AA. PMID: 26191535.
      View in: PubMed   Mentions:
    80. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. PMID: 25923550.
      View in: PubMed   Mentions: 194     Fields:    Translation:HumansCTClinical Trials
    81. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21; 372(21):2018-28. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. PMID: 25891174.
      View in: PubMed   Mentions: 1498     Fields:    Translation:HumansCTClinical Trials
    82. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 03; 348(6230):124-8. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. PMID: 25765070.
      View in: PubMed   Mentions: 1972     Fields:    Translation:HumansCells
    83. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. PMID: 25611228.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    84. Representing and extracting lung cancer study metadata: study objective and study design. Comput Biol Med. 2015 Mar; 58:63-72. Garcia-Gathright JI, Oh A, Abarca PA, Han M, Sago W, Spiegel ML, Wolf B, Garon EB, Bui AA, Aberle DR. PMID: 25618216.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    85. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015 Feb; 20(2):224-6. Ou SH, Sommers KR, Azada MC, Garon EB. PMID: 25568147.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    86. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. PMID: 27279236.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    87. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. PMID: 25535693.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    88. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Crit Rev Oncog. 2015; 20(5-6):339-47. Garon EB, Abarca PA, Strunck JL, Nameth D, Neumann C, Wolf B, Kim KY, Marx C, Elashoff RM. PMID: 27279233.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    89. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8. Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. PMID: 25516338.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    90. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23; 384(9944):665-73. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. PMID: 24933332.
      View in: PubMed   Mentions: 285     Fields:    Translation:HumansCTClinical Trials
    91. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. PMID: 24846037.
      View in: PubMed   Mentions: 441     Fields:    Translation:HumansCTClinical Trials
    92. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy. Clin Lung Cancer. 2014 Jul; 15(4):287-93. Rwigema JC, Chen AM, Wang PC, Lee JM, Garon E, Lee P. PMID: 24594401.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    93. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res. 2014 May; 12(5):765-74. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM. PMID: 24469837.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    94. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014 Mar; 140(3):443-52. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ. PMID: 24442098.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    95. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PMID: 24145346.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCTClinical Trials
    96. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013 Oct; 8(10):1308-16. Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju C. PMID: 23981966.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    97. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res. 2013; 5(5):481-96. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. PMID: 23977408.
      View in: PubMed   Mentions:
    98. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. PMID: 23515407.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    99. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. . 2013 Jun; 12(6):890-900. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. PMID: 23493311.
      View in: PubMed   Mentions:
    100. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. PMID: 23399957.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    101. Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S377-8. Goldman JW, Garon EB. PMID: 23160324.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    102. Expanding options for EGFR targeting in lung cancer. Transl Lung Cancer Res. 2012 Dec; 1(4):287-8. Chou T, Finn RS, Garon EB. PMID: 25806196.
      View in: PubMed   Mentions:
    103. The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag. 2012 Dec; 1(4):259-272. Kazmi N, Márquez-Garbán DC, Aivazyan L, Hamilton N, Garon EB, Goodglick L, Pietras RJ. PMID: 23650476.
      View in: PubMed   Mentions:
    104. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB. PMID: 22982661.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    105. Uncertainty and psychological adjustment in patients with lung cancer. Psychooncology. 2013 Jun; 22(6):1396-401. Kurita K, Garon EB, Stanton AL, Meyerowitz BE. PMID: 22887017.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    106. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer. 2012 Nov; 13(6):505-9. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol M. PMID: 22853980.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    107. Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer. 2012 Sep; 77(3):475-81. Garon EB. PMID: 22795702.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    108. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci. 2012 Oct; 69(19):3341-3350. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, Chia D, Elashoff D, Park NH, Wong DTW. PMID: 22689099.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    109. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. PMID: 22496272.
      View in: PubMed   Mentions: 170     Fields:    Translation:HumansCTClinical Trials
    110. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics. 2012 Feb; 11(2):M111.012112. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT. PMID: 22096114.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    111. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. PMID: 22045706.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    112. Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1791-2. Garon EB, Dubinett SM. PMID: 22005532.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011 Jul; 146(7):836-43. Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B, Reber HA. PMID: 21768431.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    114. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011 Aug; 76(9):910-20. Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, Horvath S, Chia D, Garon E, Goodglick L, Pietras RJ. PMID: 21600232.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    115. High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation. J Cardiothorac Surg. 2011 Feb 25; 6:19. Mong C, Garon EB, Fuller C, Mahtabifard A, Mirocha J, Mosenifar Z, McKenna R. PMID: 21352550.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    116. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011 Mar 01; 17(5):1131-9. Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. PMID: 21220471.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCellsCTClinical Trials
    117. Poly(ADP-ribose) polymerase inhibitors. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S455-6. Garon EB, Dubinett SM. PMID: 21102236.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Novel drugs--miscellaneous category. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S468-9. Hosmer WD, Dubinett SM, Garon EB. PMID: 21102242.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Proapoptotic agents in lung cancer. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S480-1. Ujhazy P, Garon EB. PMID: 21102248.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. Management of small-cell lung cancer: time to move forward. Oncology (Williston Park). 2010 Oct; 24(11):1043, 1046-7. Pollock J, Garon EB. PMID: 21155456.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    121. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. . 2010 Jul; 9(7):1985-94. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. PMID: 20587667.
      View in: PubMed   Mentions:
    122. Intracellular signaling molecules. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1057-8. Garon EB, Dubinett SM. PMID: 19861915.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    123. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008 Feb; 3(2):107-10. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM. PMID: 18303428.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    124. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1405-21. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. PMID: 17944566.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    125. In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer. 2007 Aug 01; 121(3):675-82. Garon EB, Sawcer D, Vernier PT, Tang T, Sun Y, Marcu L, Gundersen MA, Koeffler HP. PMID: 17417774.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    126. Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells. Leuk Res. 2007 May; 31(5):643-51. Garon EB, Marcu L, Luong Q, Tcherniantchouk O, Crooks GM, Koeffler HP. PMID: 17027955.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    127. Nanoelectropulse intracellular perturbation and electropermeabilization technology: phospholipid translocation, calcium bursts, chromatin rearrangement, cardiomyocyte activation, and tumor cell sensitivity. Conf Proc IEEE Eng Med Biol Soc. 2005; 2005:5850-3. Vernier PT, Sun Y, Wang J, Thu MM, Garon E, Valderrabano M, Marcu L, Koeffler HP, Gundersen MA. PMID: 17281590.
      View in: PubMed   Mentions: 6     Fields: